vTv Therapeutics Inc. Forecasted to Earn FY2023 Earnings of ($0.29) Per Share (NASDAQ:VTVT)

vTv Therapeutics Inc. (NASDAQ:VTVT – Get Rating) – Analysts at Cantor Fitzgerald cut their FY2023 earnings per share estimates for vTv Therapeutics in a research note issued on Monday, March 13th. Cantor Fitzgerald analyst C. Duncan now expects that the biotechnology company will post earnings per share of ($0.29) for the year, down from their prior estimate of ($0.27). The consensus estimate for vTv Therapeutics’ current full-year earnings is ($0.31) per share.

Several other analysts also recently commented on VTVT. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of vTv Therapeutics in a research report on Tuesday, March 7th. StockNews.com started coverage on shares of vTv Therapeutics in a report on Thursday. They issued a “hold” rating for the company.

vTv Therapeutics Stock Performance

Shares of VTVT opened at $0.80 on Thursday. The firm has a market cap of $83.40 million, a PE ratio of -3.19 and a beta of -1.11. The firm’s 50 day moving average price is $0.87 and its 200 day moving average price is $0.87. vTv Therapeutics has a twelve month low of $0.38 and a twelve month high of $1.40.

vTv Therapeutics (NASDAQ:VTVT – Get Rating) last posted its quarterly earnings results on Monday, March 6th. The biotechnology company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06). The firm had revenue of $0.01 million for the quarter.

Hedge Funds Weigh In On vTv Therapeutics

A number of institutional investors have recently modified their holdings of the company. Prudential Financial Inc. acquired a new stake in shares of vTv Therapeutics in the second quarter valued at about $30,000. HBK Sorce Advisory LLC acquired a new stake in vTv Therapeutics in the 4th quarter valued at approximately $38,000. Millennium Management LLC grew its holdings in vTv Therapeutics by 12.0% in the 2nd quarter. Millennium Management LLC now owns 138,683 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 14,845 shares during the last quarter. Finally, State Street Corp increased its position in vTv Therapeutics by 268.7% in the 2nd quarter. State Street Corp now owns 206,145 shares of the biotechnology company’s stock worth $155,000 after buying an additional 150,228 shares during the period. Institutional investors own 8.50% of the company’s stock.

About vTv Therapeutics

(Get Rating)

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer.